Ofatumumab for treating autoimmune nodopathy
Journal of the Peripheral Nervous System · 2025
DOI: 10.1111/jns.12679 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Jianian Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Background and Aims To investigate the treatment of ofatumumab in autoimmune nodopathy (AN).
Methods
An open‐label, prospective, observational study was conducted in patients with AN. The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and subsequently every 4 weeks in a total of 24 weeks. The primary endpoint of the study was the proportion of patients with confirmed clinical improvement.
Results
All of the eight patients (100%) improved at Week 24. The median time to improvement was 8 (IQR: 7–10) weeks. The four patients previously treated with rituximab and two with irregular injections of ofatumumab (OFA) improved. At Week 24, the adjusted INCAT score, MRC sum score, cI‐RODS, and grip strength in nondominant hand significantly improved from baseline. In nerve conduction studies, all of the six patients with available data (100%) improved. The median sNfL significantly reduced from baseline at Week 8. Anti‐paranodal antibody in seven patients with anti‐NF155 antibodies reduced from baseline at Week 20. In seven of the eight patients, CD19+ B cells were significantly reduced at Week 4. No serious adverse events were reported.
Interpretation
The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and every 4 weeks from Week 4, in a total of 24 weeks. The ofatumumab therapy may provide a more convenient and safer treatment for patients with AN, while serving as an effective alternative for those who did not respond to rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
- Rare Disease Center, Huashan Hospital Fudan University, Shanghai, China.
- National Center for Neurological Disorders (NCND), Shanghai, China.
ORCID-Profile: Jianian Hu, Yongsheng Zheng
Förderung
- Shanghai Municipal Science and Technology Major Project
Zitieren
APA
Hu, J., Zheng, Y., Sun, C., Sun, J., Xi, J., Luo, S., Qiao, K., Zhao, C., & Lin, J. (2025). Ofatumumab for treating autoimmune nodopathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12679
Vancouver
Hu J, Zheng Y, Sun C, Sun J, Xi J, Luo S, et al. Ofatumumab for treating autoimmune nodopathy. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.12679
BibTeX
@article{Hu2025,
author = {Hu, Jianian and Zheng, Yongsheng and Sun, Chong and Sun, Jian and Xi, Jianying and Luo, Sushan and Qiao, Kai and Zhao, Chongbo and Lin, Jie},
title = {Ofatumumab for treating autoimmune nodopathy},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
doi = {10.1111/jns.12679}
}
EUVIMED